How we operate
Northern Leaf employs the highest standards of cultivation and operational best practice
Led by a diverse team of highly experienced sector and functional experts and operating to strict pharmaceutical regulation, Northern Leaf is positioned to become a leader in Europe in the cultivation and supply of high quality and consistent cannabis-based medicines.
The significant investment into our facility gives us the control we need over our growing and processing conditions – a key element in enabling consistency, batch after batch.
We have invested £30m to complete a state-of-the-art cannabis facility
And are now well positioned to become the european leader in the delivery of high-quality, consistent cannabis-based medicines.
Our process
Northern Leaf operates from a 100,000 sq.ft facility that, at capacity, can produce 6-8 tonnes of dried flower per annum.
Our processes are designed to produce the quality and consistency that is required by prescribing physicians and patients globally. Our end product is an Active Pharmaceutical Ingredient (“API”), governed by EU-GMP Part II which is used to manufacture finished medicines.
Our People
Introducing our team of diverse experts
